The introduction of a medical device into the U.S. market in 2026 is not just about demonstrating safety and performance anymore. It now calls to show high regulatory preparedness and cybersecurity preparedness, and explicit risk management throughout the product lifecycle. Due to the constantly growing demands of software-driven and connected medical devices by the FDA, the use of professional US FDA consultants has become a necessity instead of a luxury.
https://qualysec.com/us-fda-consultants/
The reviews done by FDA nowadays go way beyond the conventional clinical evidence. The manufacturers of medical devices are supposed to provide comprehensive cybersecurity documentation, a designed risk assessment, and postmarket security monitoring plans. Even well-crafted devices will suffer approval lag, extra information demands, or Not Substantially Equivalent results when the regulatory or cybersecurity voids are found in review.
Top comments (0)